Ambulatory Ambliopia NovaSight offers CureSight, an eye-tracking based digital therapy for amblyopia that can be used at home with real time monitoring and AI-driven protocol adjustments. This creates a sales opportunity with pediatric clinics, hospitals, and telemedicine platforms seeking effective, home-based treatment options with remote caregiver feedback.

Screening Modernization EyeSwiftPRO provides automated, portable vision screening that delivers quick, objective assessments. Target potential buyers include school health programs, pediatric practices, and family clinics looking to replace manual, time consuming screening methods with faster, data-driven solutions.

Regulatory Momentum CureSight achieved FDA 510 clearance and recently expanded market introduction in the United States. This regulatory milestone can be leveraged to approach UL/CE markets, build trust with procurement teams, and pursue hospital and clinic integrators seeking compliant, scalable therapies.

Strategic Partnerships Funding and investor activity, along with partnerships hinted by cross-industry interest, suggest opportunities to collaborate with pharmaceutical and medical device companies and distributors that can broaden CureSight and EyeSwiftPRO reach into new geographies and care pathways.

Growth indicators Revenue range and early-stage funding position NovaSight as a growing MedTech player with a scalable model. This supports outreach to health systems and GPOs looking for innovative vision care solutions with measurable outcomes and potential telemedicine integrations.